Adaptive designs for confirmatory clinical trials

被引:168
作者
Bretz, Frank [2 ,3 ]
Koenig, Franz [1 ]
Brannath, Werner
Glimm, Ekkehard [2 ]
Posch, Martin
机构
[1] Med Univ Vienna, Sect Med Stat, Core Unit Med Stat & Informat, A-1090 Vienna, Austria
[2] Novartis Pharma AG, CH-4002 Basel, Switzerland
[3] Hannover Med Sch, Dept Biometry, D-30623 Hannover, Germany
关键词
adaptive seamless design; design modification; flexible design; combination test; conditional error rate; interim analysis; many-to-one comparisons; treatment selection; GROUP SEQUENTIAL DESIGNS; SAMPLE-SIZE; HYPOTHESES SELECTION; UNBIASED ESTIMATION; INTERIM; TESTS; POWER;
D O I
10.1002/sim.3538
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Adaptive designs play an increasingly important role in clinical drug development. Such designs use accumulating data of an ongoing trial to decide how to modify design aspects without undermining the validity and integrity of the trial. Adaptive designs thus allow for a number of possible adaptations at midterm: Early stopping either for futility or success, sample size reassessment, change of population, etc. A particularly appealing application is the use of adaptive designs in combined phase II/III Studies with treatment selection at interim. The expectation has arisen that carefully planned and conducted studies based on adaptive designs increase the efficiency of the drug development process by making better use of the observed data, thus leading to a higher information value per patient. In this paper we focus on adaptive designs for confirmatory clinical trials. We review the adaptive design methodology for a single mill hypothesis and how to perform adaptive designs with multiple hypotheses using closed test procedures. We report the results of an extensive simulation study to evaluate the operational characteristics of the various methods. A case study and related numerical examples are used to illustrate the key results. In addition we provide a detailed discussion of current methods to calculate point estimates and confidence intervals for relevant parameters. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:1181 / 1217
页数:37
相关论文
共 80 条
[1]  
[Anonymous], 1987, MULTIPLE COMP PROCED, DOI DOI 10.1002/9780470316672
[2]  
Bauer P, 1999, STAT MED, V18, P1833, DOI 10.1002/(SICI)1097-0258(19990730)18:14<1833::AID-SIM221>3.0.CO
[3]  
2-3
[4]   The reassessment of trial perspectives from interim data - a critical view [J].
Bauer, P ;
Koenig, F .
STATISTICS IN MEDICINE, 2006, 25 (01) :23-36
[5]  
Bauer P, 1996, BIOMETRICS, V52, P380
[6]  
Bauer P., 1989, BIOMETRIE INFORMATIK, V20, P130
[8]  
Berry D., 2002, LECT NOTES STAT, V5, P99
[9]   Innovative approaches for designing and analyzing adaptive dose-ranging trials [J].
Bornkamp, Bjoern ;
Bretz, Frank ;
Dmitrienko, Alex ;
Enas, Greg ;
Gaydos, Brenda ;
Hsu, Chyi-Hung ;
Koenig, Franz ;
Krams, Michael ;
Liu, Qing ;
Neuenschwander, Beat ;
Parke, Tom ;
Pinheiro, Jose ;
Roy, Amit ;
Sax, Rick ;
Shen, Frank .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) :965-995
[10]   Unbiased estimation of selected treatment means in two-stage trials [J].
Bowden, Jack ;
Glimm, Ekkehard .
BIOMETRICAL JOURNAL, 2008, 50 (04) :515-527